HIV sales prop up Gilead’s 3Q as Yescarta misses estimates

Gilead leaned on its HIV franchise to meet the Street’s expectations on its 3Q19 results, as HCV sales continued to fall and the company’s high-profile cell therapy Yescarta missed revenue expectations.

Gilead Sciences Inc. (NASDAQ:GILD) reported non-GAAP EPS of $1.75 on revenues of $5.6 billion

Read the full 446 word article

User Sign In